About NeoGenomics
NeoGenomics is a company based in Fort Myers (United States) founded in 2002. It operates as a Professional Services and Data-as-a-Service. The company has 2,200 employees as of December 31, 2024. NeoGenomics has completed 7 acquisitions, including GE Healthcare, Genoptix and Inivata. NeoGenomics offers products and services including PanTracer Tissue, Paletrra, and Comprehensive Genomic Profiling. NeoGenomics operates in a competitive market with competitors including Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others.
- Headquarter Fort Myers, United States
- Employees 2200 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Neogenomics, Inc.
-
Annual Revenue
$660.57 M (USD)11.65as on Dec 31, 2024
-
Net Profit
-$78.73 M (USD)10.51as on Dec 31, 2024
-
EBITDA
$852 K (USD)0as on Dec 31, 2024
-
Latest Funding Round
$345 M (USD), Post-IPO
Jan 20, 2021
-
Investors
Not available
-
Employee Count
2200
as on Dec 31, 2024
-
Investments & Acquisitions
GE Healthcare
& 6 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of NeoGenomics
NeoGenomics is a publicly listed company on the NASDAQ with ticker symbol NEO in USA, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of NeoGenomics
NeoGenomics offers a comprehensive portfolio of products and services, including PanTracer Tissue, Paletrra, and Comprehensive Genomic Profiling.
Comprehensive genomic profiling for solid tumor diagnostics is provided.
Spatial proteomics insights for tissue analysis are delivered effectively.
Advanced genomic profiling for cancer diagnostics is offered here.
People of NeoGenomics
Unlock access to complete
Unlock access to complete
Funding Insights of NeoGenomics
Investments & Acquisitions by NeoGenomics
NeoGenomics has strategically engaged in corporate development activities, having acquired 7 companies. Notable acquisitions include GE Healthcare, Genoptix and Inivata.
Investment portfolio details for NeoGenomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Liquid biopsy platform for cancer detection is developed.
|
Locked | Locked | 2014 | Locked | |
|
Pathology laboratory services are provided independently in the United States.
|
Locked | Locked | 2009 | Locked | |
|
Precision medicine platform is provided for oncologists' decision support.
|
Locked | Locked | 2009 | Locked |
Complete acquisition details for NeoGenomics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - NeoGenomics
Detailed financials for NeoGenomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Neogenomics Comparisons
Peer comparison for NeoGenomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NeoGenomics
NeoGenomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
|
| Locked | Locked | Locked |
Genomic sequencing and diagnosis software is provided for healthcare.
|
Detailed competitors of NeoGenomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Neogenomics
Complete news archive for NeoGenomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NeoGenomics
NeoGenomics was founded in 2002 and raised its 1st funding round 7 years after it was founded.
NeoGenomics is headquartered in Fort Myers, United States. It is registered at Fort Myers, Florida, United States.
As of Dec 31, 2024, the latest employee count at NeoGenomics is 2,200.
Annual revenue of NeoGenomics is $660.57M as on Dec 31, 2024.
NeoGenomics Laboratories is focused on precision oncology diagnostics, offering a wide range of testing solutions for solid tumors and hematologic cancers. Over 500 tests are provided, including molecular testing, immunohistochemistry, flow cytometry, and next-generation sequencing. Services are tailored for oncologists, biopharma partners, and patients, supporting personalized care, drug development, and clinical trials. The company contributes to cancer research through real-world evidence and genomic insights. Testing portfolios cover lung, breast, colorectal, and other cancer types, ensuring alignment with the latest guidelines and evidence.
NeoGenomics's top competitors include Guardant Health, Foundation Medicine and Personalis.
NeoGenomics offers PanTracer Tissue, Paletrra, and Comprehensive Genomic Profiling.
Yes, NeoGenomics is publicly traded on NASDAQ under the ticker symbol NEO.
NeoGenomics has made 7 acquisitions, including GE Healthcare, Genoptix, and Inivata.
The ticker symbol of NeoGenomics is NEO on NASDAQ.